Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 74,485 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 74,485 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $67.53, for a total transaction of $5,029,972.05. Following the transaction, the chief executive officer now directly owns 5,458,502 shares in the company, valued at $368,612,640.06. The trade was a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $68.96 on Monday. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock has a 50 day moving average price of $44.49 and a two-hundred day moving average price of $49.16.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the company. Vestmark Advisory Solutions Inc. grew its stake in Tempus AI by 148.3% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 122,450 shares of the company’s stock valued at $4,134,000 after buying an additional 73,132 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Tempus AI during the fourth quarter valued at about $3,757,000. Victory Capital Management Inc. acquired a new stake in shares of Tempus AI in the fourth quarter valued at about $216,000. SBI Securities Co. Ltd. bought a new position in shares of Tempus AI in the fourth quarter worth about $673,000. Finally, US Bancorp DE acquired a new position in shares of Tempus AI during the 4th quarter worth about $80,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TEM shares. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital lowered their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Bank of America boosted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.